Human IL-2 as a vaccine adjuvant

Details Human IL-2 as a vaccine adjuvant Human IL-2 as a vaccine adjuvant

1989-02-24

1996-04-02

Walsh, Stephen G.

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

424 852, 4242071, 4242091, 4242241, 4242411, 4242551, 4242561, 4242611, 514885, A61K 3820, A61K 3902, A61K 3912

Patent

active

055038417

ABSTRACT:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.

REFERENCES:
patent: 3674862 (1972-07-01), Lavender
patent: 4196192 (1980-04-01), Kuo
patent: 4604377 (1986-08-01), Fernandes et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4780313 (1988-10-01), Koichiro et al.
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4840934 (1989-06-01), Anderson
Merlizzi et al Eur J Immunopharmac. vol. 7, 1985, pp. 31-34.
Reed et al J Immunol 1984, vol. 133, pp. 3333-3337.
Colizzi, Inf and Immunity, vol. 45, 1984, pp. 25-28.
Homberg et al, J. Immunol., vol. 130, 1983, pp. 2644-2650.
Donohue et al, J Immunol 130, 1983, 2203-08.
Ralph et al J. Immunol vol. 133, 1984, pp. 2442-2445.
Mills, J Immunol vol. 125, 1980, pp. 1904-1909.

Affiliated with

Also associated with

Rating

Human IL-2 as a vaccine adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human IL-2 as a vaccine adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human IL-2 as a vaccine adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2014894